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ABSTRACT
Background While meta-analyses confirm treatment
for chronic post-stroke aphasia is effective, a lack
of comparative evidence for different interventions
limits prescription accuracy. We investigated whether
Constraint-I nduced Aphasia Therapy Plus (CIAT-plus)
and/or Multimodality Aphasia Therapy (M-MAT)
provided greater therapeutic benefit compared with
usual community care and were differentially effective
according to baseline aphasia severity.
Methods We conducted a three-arm, multicentre,
parallel group, open-label, blinded endpoint, phase
III, randomised-controlled trial. We stratified eligible
participants by baseline aphasia on the Western Aphasia
Battery-Revised Aphasia Quotient (WAB-R-AQ). Groups
of three participants were randomly assigned (1:1:1) to
30 hours of CIAT-Plus or M-MAT or to usual care (UC).
Primary outcome was change in aphasia severity (WAB-
R-AQ) from baseline to therapy completion analysed in
the intention-to-treat population. Secondary outcomes
included word retrieval, connected speech, functional
communication, multimodal communication, quality of
life and costs.
Results We analysed 201 participants (70 in CIAT-
Plus, 70 in M-MAT and 61 in UC). Aphasia severity
was not significantly different between groups at
postintervention: 1.05 points (95% CI −0.78 to 2.88;
p=0.36) UC group vs CIAT-Plus; 1.06 points (95% CI
−0.78 to 2.89; p=0.36) UC group vs M-MAT; 0.004
points (95% CI −1.76 to 1.77; p=1.00) CIAT-Plus vs
M-MAT. Word retrieval, functional communication and
communication-related quality of life were significantly
improved following CIAT-Plus and M-MAT. Word retrieval
benefits were maintained at 12-week follow-up.
Conclusions CIAT-Plus and M-MAT were effective for
word retrieval, functional communication, and quality
of life, while UC was not. Future studies should explore
predictive characteristics of responders and impacts of
maintenance doses.
Trial registration number ACTRN 2615000618550.

INTRODUCTION

Aphasia is an acquired language disability, impacting
all aspects of communication underpinned by

Key messages
What is already known on this topic

► Previous evidence for constraint-induced

aphasia therapy (CIAT-Plus) and Multimodality
Aphasia Therapy (M-MAT) is limited by small
sample sizes, inadequate comparator groups,
and recruitment and detection bias.

What this study adds

► This large-scale, phase III trial confirmed the

efficacy of an intensive dose of CIAT Plus and
M-MAT with clinically meaningful effects on
word retrieval, functional communication and
quality of life.

How this study might affect research, practice
or policy
► CIAT Plus and M-MAT are efficacious
interventions in the chronic phase of aphasia
recovery. Research is required to explore
methods to enhance maintenance of effects
and potential impacts of aphasia severity on
treatment prescription.
language: understanding speech, reading, writing
and speaking. Aphasia persists into the chronic
phase in approximately 20% of stroke survivors,1
with significant negative impacts on mental health2
and quality of life.3 In the first year after stroke,
aphasia is responsible for 8.5% of stroke related
healthcare costs.4 The 2016 Cochrane review of
speech and language therapy for aphasia after
stroke showed statistically significant treatment
effects immediately after intervention for functional communication (SMD 0.28, 95% CI 0.06
to 0.49, p=0.01) when treatment was provided
with sufficient intensity (5–10 hours per week),
but not at 6 month follow-up.5 The review lacked
evidence for comparative treatment effects,5
limiting the prescription of effective treatment.
Additional evidence for the effectiveness of aphasia
therapy in the chronic phase (>6 months) comes
from two high quality randomised controlled trials
(RCTs): the FCET2EC trial6 and the Big CACTUS
trial.7 FCET2EC6 utilised a mean of 46 hours of
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linguistic and pragmatically focused, clinician delivered, individual therapy showing significant effects (moderate ESs) on
functional communication immediately post-intervention and at
6 month follow-up. Big CACTUS7 used computer-based naming
therapy and demonstrated significant effects (moderate ESs) on
word finding for trained items but not functional communication. Both trials6 7 confirmed significant variability in participant
treatment response, with stroke6 and aphasia severity7 as probable moderator variables. There is a need for properly powered
trials comparing the effectiveness of different aphasia treatments
in the chronic phase.
Constraint-induced Aphasia Therapy Plus (CIAT-Plus)8 and
Multimodality Aphasia Therapy (M-MAT)9 are intensive, high-
dose interventions delivered in a small group setting of 2–4
participants, aimed at improving verbal communication. They
involve different therapeutic strategies: CIAT-plus preferences
speech production and verbal therapist cueing; M-MAT includes
multimodal tasks and cues (drawing, gesturing and writing).
CIAT-Plus and M-MAT are hypothesised to rely on different
underlying neural recovery mechanisms and may be differentially effective based on aphasia severity.9 10 Systematic reviews
of trials of CIAT-Plus and M-MAT reveal moderate-high effect
sizes11–13 but studies are limited by small sample sizes (n<15),
inadequate comparator groups, and recruitment and detection
bias. Determining the most effective intervention for severity-
based and other sub-groups of people with aphasia may lead to
improved patient outcomes and reduced healthcare costs.
The aim of our multicentre RCT of constraint-induced or
multimodality personalised aphasia rehabilitation (COMPARE)
was to assess the comparative effectiveness of a 2-week intensive
dose (30 hours) of treatment (CIAT-Plus or M-MAT) in chronic
aphasia after stroke compared with low dose usual community
care (usual care, UC). We aimed to investigate potential differential impacts according to pre-treatment aphasia severity. Our
primary hypothesis was that, compared with UC, both CIAT-
Plus and M-MAT would lead to significantly reduced aphasia
severity immediately post-
intervention, with M-
MAT superior for mild and severe aphasia, and CIAT-Plus superior for
moderate aphasia.9 10 We further hypothesised that, compared
with UC, both treatments would lead to improved word
retrieval, functional communication, multimodal communication and quality of life. A tertiary objective (not reported here)
was to report on the potential incremental cost-effectiveness of
these interventions.

METHODS
Study design

COMPARE was a three-arm, multicentre, parallel group, open-
label, blinded endpoint, phase III RCT (figure 1). The trial
protocol has been published.14 CIAT-
Plus and M-
MAT were
provided by 30 trial trained therapists in community settings

Figure 1 Trial timeline. CIAT, constraint-induced aphasia therapy; M-MAT,
Multimodality Aphasia Therapy.
2

in ten cities across Australia and New Zealand. We used usual
community care as the control condition, which in Australia
and New Zealand comprises either no therapy or limited, non-
intensive therapy of less than 1 hour per week.15 The trial was
coordinated from the Aphasia Rehabilitation Research Centre at
La Trobe University in Melbourne. A data safety and management committee comprising staff independent of the principal
investigators (a biostatistician, an experienced stroke rehabilitation trialist, and a speech pathologist with additional expertise in
bioethics) monitored study progress and safety.

Participants

Eligible participants were: aged 18 years or older; living in the
community; had chronic aphasia resulting from stroke of any kind
(>6 months duration) confirmed by an aphasia quotient <93.8
on the Western Aphasia Battery-
Revised Aphasia Quotient
(WAB-R-AQ)16 at the time of screening; fluent in English prior
to stroke; independent in toileting or had a caregiver who could
assist with toileting during therapy. Participants provided their
own written informed consent. Modified consent processes
were provided including the use of supported communication
strategies and aphasia accessible consent documents. Participants
were excluded if they had a neurological condition other than
stroke, severe apraxia of speech or dysarthria (Apraxia Severity
Rating Scale)17 uncorrected sensory loss preventing participation in group communication, or a diagnosis of a self-reported
untreated mental health condition preventing adherence to the
study protocol. Participants were recruited through 19 hospital
sites and via direct community advertising.

Randomisation and masking

Therapy was provided face to face, in groups of three participants, requiring the members of a treatment group to be in the
same geographic location. Once enrolled in the trial, participants were allocated to treatment groups based on their aphasia
severity (WAB-
R-
AQ mild: 93.7–62.6; moderate: 62.5–31.3;
severe:≤31.3). Groups of three participants were randomised to
one of three arms (M-MAT, CIAT-Plus or UC) in a 1:1:1 ratio via
a central allocation system using blocked randomisation within
each severity stratum. Only the independent randomisation statistician knew the block sizes, and these were not disclosed until
trial completion. COMPARE involved complex behavioural
interventions in which the treating therapists were aware of the
treatment they provided. Participants assigned to UC were aware
they were not receiving intensive treatment. Therefore, neither
the participants nor the treating therapists were blinded. All
assessments were conducted by independent assessors who were
blinded to treatment allocation.

Procedures

Full details of the intervention are provided in the published
COMPARE Trial protocol14 and online trial (https://cloudstor.
aarnet.edu.au/plus/s/dkST1BSrG6r8ooT)
and
intervention
protocols (https://cloudstor.aarnet.edu.au/plus/s/F74O828J71IDYKa;
https://cloudstor.aarnet.edu.au/plus/s/crCAZe09ggGCosV). We used the Template for Intervention Description
and Replication reporting template18 to guide reporting of this
complex behavioural intervention (online supplemental material
p.4).
CIAT-Plus and M-MAT treatment sessions ran 3 hours a day,
5 days per week for 2 weeks (30 hours). Rest breaks of 15–30
min were provided between every 1-hour session. A 15 min daily
home practice communication task was prescribed, checked for
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completion the following day, and logged in the COMPARE
Research Electronic Data Capture (REDCap) database. CIAT-
Plus and M-
MAT were provided in community settings by
qualified and study-trained speech pathologists. UC comprised
no direct intervention for some, and non-intense, individual,
computerised or social/support group sessions for others. UC
logged diary, collected by
was documented in a participant-
blinded assessors at the baseline and 12-week follow-up time
points. All participants could undertake UC throughout the trial
allowing for the effects of UC alone to be compared with the
addition of 2 weeks of CIAT-Plus or M-MAT.
Plus and M-
MAT involved six different structured,
CIAT-
protocolised communication activities including requesting
items, clarifying requests, recalling items from memory and
naming items. A prescribed set (easy, moderate, hard) of 80
coloured picture cards (48 nouns; 32 verbs) was utilised in
therapy according to participant pretreatment picture naming
accuracy. Therapists prescribed production targets ranging from
single nouns/verbs to complex sentences. Therapist decisions to
select targets and picture sets were guided by a detailed protocol.
All session details and individual participant performance were
logged in the trial REDCap database.
In CIAT-Plus, participants were not permitted to use paper
and pencil or augmentative communication devices, focusing
all activity on spoken communication. Visual barriers (23 cm
high) placed between participants blocked sight of therapy stimulus cards, limiting nonverbal communication attempts. When
participants could not spontaneously produce specific targets
(word, phrase, sentence) within 10 s, the therapist commenced
a strict cueing hierarchy: (1) provision of initial sound of target
(eg, starts with ‘/k/’); (2) provision of written form of target to
read aloud (eg, cup); (3) spoken form of target provided for the
participant to repeat aloud three times. In M-MAT, multimodal
communication and cues were utilised and there were no visual
barriers. When participants could not spontaneously produce
targets, therapists implemented a strict cueing hierarchy: (1)
participant asked to produce a gesture of, and attempt to name,
the target; (2) therapist provided gesture and spoken target word
for participant to copy; (3) participant asked to draw target and
name it; (4) participant provided with written target to read
aloud and repeat three times. All therapy sessions were videorecorded and monitored by an independent therapy fidelity
monitor. All videos from day 1 of intervention and 25% of day 6
were reviewed for therapy adherence, with feedback to therapists
within 24 hours of receipt (fidelity monitoring protocol online
https://cloudstor.aarnet.edu.au/plus/s/k37xblJGkSsxLYR).
Demographic, medical/health, mood, speech and language
characteristics were collected at screening prior to study inclusion (table 1; online supplemental material p.5). All primary
and secondary outcomes were collected within 2 weeks prior
to the intervention period commencing (baseline), within 7 days
of ending the intervention (immediate postintervention), and
within 7 days of the 12-week follow-up time point. All assessment data were collected in participants’ homes except for
15 participants (30 assessments) due to COVID-19 pandemic
hospital and university policies requiring completion via video
teleconference. Validity of video teleconference administration
of the outcome measures have been shown to be equivalent to
face to face.19 20

Outcomes

Outcomes included four of the recommended measures from the
core outcome set for aphasia studies.21 The primary outcome

measure was change in aphasia severity from baseline to immediately post-intervention as assessed by the WAB-R-AQ. Secondary
outcomes included change in word retrieval (COMPARE
naming battery: treated 80-item set; untreated 100-item set13
(online supplemental material p.1)), functional communication
(Communication Effectiveness Index (CETI)22), multimodal
communication (Scenario Test,23 quality of life (Stroke and
Aphasia Quality of Life Scale-
39g (SAQOL-
39g),24 and efficiency of connected speech (correct information units (CIUs)/
min.25 Additional secondary outcomes included maintenance of
treatment effects as measured by repeating all outcome measures
at a 12-week follow-up visit. All adverse events were reported
to the study coordination team within 24 hours of occurrence.
All serious adverse events were reported to the trial steering
committee and the lead Human Research Ethics Committee.

Statistical analysis
The published statistical analysis plan provides full details of the
analyses and was submitted for publication ahead of database
lock (September 2020).26 At the time of study design, a 5-point
difference on the WAB-R-AQ was considered clinically meaningful.27 Therefore, the study was powered to detect a 5-point
difference on the WAB-R-AQ at therapy completion. Given
previous reports of moderate effect sizes following CIAT-Plus
and M-MAT, and without considering a possible clustering effect
for group intervention, a sample size of 198 was required to
achieve 80% power at the 5% significance level. Adjusting for
the clustering effect, we anticipated a relatively small intraclass
correlation coefficient of 0.04 and, with a group size of three, we
calculated a maximum design effect of 1.08. We multiplied this
design effect to the naïve (unclustered) sample size of 198, and
rounded off to a multiple of three, to obtain balanced allocation
across the three treatment groups, yielding the required sample
size of 216.
All statistical analyses were performed by a statistician not
employed at the trial coordination centre (TR). Analyses for
all outcome measures were conducted on an intention to treat
basis. Imputation for missing data was not required as <10% of
primary outcome data were missing. The planned per-protocol
analysis was also not required as only five participants in CIAT-
Plus and two in M-MAT did not receive the minimum 24 hours
of intervention.
We used linear mixed effects regression models for the
primary outcome analysis with WAB-
R-
AQ as the outcome
measure, adjusted for baseline aphasia severity (WAB-R-AQ) and
baseline stroke severity (mRS) as fixed effects; treatment group
and individual/participant were included as random effects. 95%
CIs were calculated and reported. For all secondary outcomes,
we used linear mixed effects regression models with CIUs/
min, CETI, Scenario Test, SAQOL-39g or COMPARE Naming
Battery as the outcome measure, adjusted for baseline aphasia
severity (WAB-R-AQ), baseline stroke severity (mRS) and baseline score of the relevant outcome measure as fixed effects, with
treatment group and participant as random effects. The potential impacts of aphasia severity on outcomes were analysed with
linear mixed effects regression models with group allocation and
baseline severity included as an interaction term, while between
group differences were assessed with group allocation and timepoint as an interaction term. Unadjusted results for both primary
and secondary analyses are reported (online supplemental material p.7). All analyses were conducted using the R Statistical
Programming Language (V.4.0.5).28
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Table 1

Baseline characteristics of intention to treat population and therapy characteristics
CIAT Plus (n=71)

M-MAT (n=75)

UC (n=70)

Recruitment region
 Australia
 New Zealand

71 (100%)
0 (0%)

60 (80%)

64 (91.43%)

15 (20%)

6 (8.57%)

Sex
 Male

46 (64.79%)

53 (70.67%)

48 (68.57%)

 Female

25 (35.21%)

22 (29.33%)

22 (31.43%)

Age at time of consent (median (IQR)

63.93 (19.79)

63.77 (21.02)

63.16 (14.10)

 <55

21 (29.58%)

25 (33.33%)

14 (20%)

 55–70

26 (36.62%)

30 (40%)

35 (50%)

 >70

24 (33.80%)

20 (26.67%)

21 (30%)

Education (median (IQR)

14 (5)

13 (6)

14 (5)

Time post most recent stroke onset (years) (median (IQR)

2.41 (4.22)

2.97 (3.81)

2.58 (2.87)

 Low (0–2)

29 (41.43%)

30 (41.67%)

31 (48.44%)

 High (3–6)

41 (58.57%)

42 (58.33%)

33 (51.56%)

 Haemorrhage

19 (26.76%)

16 (21.33%)

13 (18.57%)

 Infarct

44 (61.97%)

48 (64%)

48 (68.57%)

Baseline mRS

Stroke type

 Infarct and haemorrhagic

1 (1.41%)

4 (5.33%)

3 (4.29%)

 Not known

7 (9.86%)

7 (9.33%)

6 (8.57%)

Aphasia type
 Anomic

32 (45)

29 (39)

30 (43)

 Broca’s

20 (28)

18 (24)

15 (21)

 Conduction

13 (18)

16 (21)

11 (16)

 Wernicke’s

4 (6)

6 (8)

9 (13)

 Global

0 (0)

2 (3)

0 (0)

 Transcortical motor

0 (0)

1 (1)

2 (3)

 Transcortical sensory

0 (0)

1 (1)

0 (0)

 Unclassifiable

2 (3)

2 (3)

WAB-R-AQ
 Above cut-off (93.7–100)

71.33 (16.98)

68.68 (19.57)

3 (4)
72.69 (18.13)

1 (1.21%)

1 (1.33%)

 Mild (62.6–93.6)

51 (71.83%)

49 (65.33%)

49 (70%)

 Moderate (31.3–62.5)

17 (23.94%)

21 (28%)

18 (25.71%)

 Severe (0–31.2)

2 (2.82%)

4 (5.33%)

3 (4.29%)

0 (0%)

WAB-R-AQ subtests
 Spontaneous speech (mean, SD) /20

14.03 (4.24)

13.43 (4.35)

14.41 (4.32)

 Auditory Verbal Comprehension (mean, SD)
 /10

8.23 (1.29)

7.89 (1.72)

8.08 (1.61)

 Repetition (Mean, SD) /10

6.65 (2.20)

6.28 (2.52)

6.57 (2.41)

 Naming and Wording Finding (mean, SD)
 /10

6.75 (2.24)

6.74 (2.49)

7.28 (1.93)

COMPARE Naming Battery (mean, SD)
/80 (treated items)

40.46 (18.38)

40.91 (18.85)

47.33 (17.38)

COMPARE Naming Battery (mean, SD)
/100 (untreated items)

61.41 (28.06)

60.63 (31.06)

67.74 (25.73)

Communication accuracy and efficiency
 No of CIUs (mean, SD)

217.04 (183.13)

178.4 (146.1)

235.72 (176.31)

 CIUs per minute (mean, SD)

22.82 (17.02)

20.30 (16.29)

27.86 (19.1)

Communicative Effectiveness Index (mean, SD) /100

56.49 (17.43)

52.28 (17.64)

59.28 (16.82)

Scenario test (mean, SD) /54

45.33 (11.16)

44.03 (10.85)

46.55 (8.64)

 Composite (mean, SD) /5

3.72 (0.62)

3.67 (0.74)

3.69 (0.56)

 Physical (mean, SD) /5

4.08 (0.76)

4.1 (0.89)

4.1 (0.74)

 Communication (mean, SD) /5

3.08 (0.86)

2.89 (0.88)

3.05 (0.72)

 Psychosocial (mean, SD) /5

3.63 (0.81)

3.59 (0.92)

3.56 (0.76)

29.20 (3.02)

29.91 (2.69)

Stroke and Aphasia Quality of Life Scale-39g

Trial provided intervention
 No of therapy hours (median (IQR)

NA
Continued
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Table 1

Continued
CIAT Plus (n=71)

M-MAT (n=75)

UC (n=70)

 Length of sessions (mean minutes (SD))

59.35 (1.67)

59.80 (1.42)

NA

 Intervention compliant (>24 hours)

65

68

NA

 No

40 (56.3%)

52 (69.3%)

47 (67.1%)

 Yes

31 (43.7%)

23 (30.7%)

23 (32.9%)

 No of speech therapy sessions (median (IQR)

10 (5, 28)

Non trial provided intervention

9 (3, 24)

10 (5, 20)

Stimulus set
 Easy
 Moderate
 Hard

12 (16.9%)

18 (24%)

NA

8 (11.27%)

2 (2.67%)

NA

51 (71.83%)

55 (73.33%)

NA

CIAT-Plus, Constraint-Induced Aphasia Therapy Plus; CIUs, correct information units; COMPARE, Constraint-Induced or Multi-Modality Personalised Aphasia Rehabilitation; M-
MAT, Multimodality Aphasia Therapy; mRS, Modified Rankin Scale; N/A, not available; UC, usual care; WAB-R-AQ, Western Aphasia Battery-Revised Aphasia Quotient.

RESULTS

We screened 342 potential participants for eligibility, and
249 eligible participants consented to the trial (figure 2). We
randomised 216 from the 249 eligible participants in groups of
three according to their severity strata and geographical location
between 15 July 2016 and 30 March 2021: 71 (33%) participants were randomised to CIAT-Plus, 75 (35%) to M-MAT
and 70 (32%) to UC. Three participants elected to drop out
before commencing treatment, and three were not provided
with M-MAT due to COVID-19 restrictions forcing cancellation of their therapy group. Nine participants from UC discontinued due to dissatisfaction with group allocation. In total, 201
(93.1%) participants completed postintervention assessment
and were included in the primary analysis (70 CIAT-Plus, 70
M-
MAT, 61 UC). COVID-
19 data collection restrictions led
to 15 participants undertaking postintervention and follow-up
assessments via video teleconference (figure 2).
Baseline demographic and clinical characteristics are reported
in table 1 (online supplemental material p.5). The median age
of all participants was 63.6 years (IQR 18.7) with a range of
18–92 years and 147 (68%) were male. At baseline, 154 (71.3%)
participants had mild aphasia, 56 (25.9%) were moderate and
6 (2.8%) were severe. Participants were a median of 2.55 years
(IQR 3.75 years) post-stroke (range 6.4 months to 28 years).
Intervention groups were broadly similar at baseline although
UC participants were more independent (lower mRS score),
were younger, had no participants with severe aphasia, and had
higher discourse and naming scores.
A median of 29.2 hours (IQR 3.02) of intervention was
provided in CIAT-Plus and 29.9 hours (IQR 2.69) in M-MAT
(table 1). Seventy-seven participants undertook non-trial related
UC speech therapy during the study period. As expected, this
comprised low dose and low intensity intervention, with a
median of ten therapy sessions (IQR 15) or approximately 7.5
hours across the 15 week trial period (table 1). Trial therapy
integrity was high: 124 (97.7%) of reviewed sessions were
adherent at day 1; 121 (100%) at day 6 (online supplemental
material p.4).
For the primary outcome measure (WAB-R-AQ), on average
there were no significant differences between the three arms
immediately post-intervention and no within group baseline to
post-intervention average change that exceeded the prespecified
5-point clinically meaningful difference (table 2, figure 3). Participant sex, age and stroke severity did not significantly moderate
the primary outcomes (online supplemental material p.9–10).
At post-intervention there was a significant difference between
CIAT-
Plus and M-
MAT for participants with severe aphasia

favouring M-MAT (difference of 7.83 points (95% CI 0.87 to
14.8); p=0.03) and for moderate aphasia favouring CIAT-Plus
(difference of 3.71 points (95% CI 1.06 to 6.36); p=0.006), but
no difference for mild aphasia (difference 0.93 (95% CI −0.71
to 2.56); p=0.26). At 3 months follow-up, there was a significant difference between CIAT Plus and UC favouring UC (difference of 2.39 points (95% CI 0.53 to 4.24); p=0.008) and there
was a significant difference (two points, (95% CI 0.38 to 3.67),
p=0.02) favouring M-MAT for people with mild aphasia, but no
other significant differences (table 2).
Significant differences were found on secondary outcomes
immediately post-
intervention (table 2, figure 3): Functional
communication (CETI) was significantly better for M-
MAT
compared with UC (4.64 (95% CI 0.32 to 8.95); p=0.032)
and CIAT-
Plus compared with UC (4.32 (95% CI 0.03 to
8.61); p=0.048) but there was no difference between CIAT-
Plus and M-MAT (0.31 (95% CI −3.81 to 4.44); p=0.98). For
communication-related quality of life (SAQOL-39 g Communication Scale), there were significant differences favouring CIAT-
Plus over UC (0.20 (95% CI 0.01 to 0.39); p=0.039), M-MAT
over UC (0.43 (95% CI 0.24 to 0.62); p=0.0001) and M-MAT
over CIAT-
Plus (0.24 (95% CI 0.05 to 0.42); p=0.008).
Compared with UC, naming of treated items was significantly
better following M-
MAT (7.49 (95% CI 4.58 to 10.41);
p<0.0001) and CIAT-
Plus (10.73 (95% CI 7.83 to 13.63);
p<0.0001), and for CIAT-Plus compared with M-MAT (3.24
(95% CI 0.43 to 6.05); p=0.019). Multimodal communication
(Scenario test) was significantly better for M-MAT compared
with CIAT-Plus (1.88 (95% CI 0.195 to 3.57); p=0.025) but
there were no differences between CIAT-Plus and UC (−1.57
(95% CI −0.15 to 3.29); p=0.08) or M-MAT and UC (0.31
(95% CI −1.40 to 2.02); p=0.90. There were minimal impacts
of the intervention on discourse measures with high levels of
baseline variability (online supplemental material p.8).
Thirty-six serious adverse events occurred during the trial for
31 participants; 18 (3.6 per year) in CIAT-Plus, 10 (1.4 per year)
in M-MAT and 8 (1.8 per year) in UC; all were deemed unrelated to study participation (table 3).

DISCUSSION

We present data from the first phase III, multisite, trial comparing
an intensive dose of CIAT-Plus or M-MAT to UC in a large,
inclusive sample of people with chronic post-
stroke aphasia.
Overall, on average, 30 hours of CIAT-Plus or M-MAT delivered over 2 weeks did not significantly reduce global aphasia
severity compared with limited community UC. However,
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Figure 2 CONSORT diagram. CETI, Communication Effectiveness Index; CIAT, Constraint-Induced Aphasia Therapy; CONSORT, Consolidated Standards of
Reporting Trials; SAQOL, Stroke and Aphasia Quality of Life; WAB-R-AQ, Western Aphasia Battery-Revised Aphasia Quotient.
baseline aphasia severity may impact outcome, with differences
between WAB-R-AQ at post-intervention favouring CIAT-Plus
for moderate aphasia, M-MAT for severe aphasia, and M-MAT
for mild aphasia at follow-up. Compared with UC, both treatments significantly improved word retrieval, functional communication and communication-related quality of life with M-MAT
superior for communication-related quality of life and CIAT-
Plus superior for word retrieval. These are important differential findings rejecting the ‘one size fits all’ approach to aphasia
therapy prescription in this highly heterogenous population. The
results are a major step forward towards more targeted allocation of aphasia treatment and personalised rehabilitation.
Most previous studies of Constraint and Multimodal aphasia
therapies for chronic aphasia utilised non-randomised designs
or were small phase I or II pilot trials subject to participant
6

selection and other biases.8 9 11–13 These study limitations may
account for the differences in findings between COMPARE and
those of the preliminary trials that showed significant change
in global aphasia severity. We utilised liberal inclusion criteria
without limitations on age or time after stroke onset beyond
the minimum of 6 months, whereas the previous studies had
narrower selection criteria which may have impacted outcomes.
Given recent trial evidence it is perhaps unsurprising that global
aphasia severity (WAB-R-AQ) was not reduced across the entire
treated population in COMPARE. For example, in FCT2EC6 only
people <70 years were recruited while in COMPARE there was
no age restriction, and participants in FCET2EC were provided
a higher dose (median of 46 hours including self-practice) of
therapy. In FCET2EC, significant improvements were observed
in functional communication which were maintained at 6 month
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Table 2

Treatment effects at immediately postintervention and 12-week follow-up in the intention-to-treat population
CIAT Plus

M-MAT

Usual care

Unadjusted
mean change
score PIV-
Baseline (SD)

Unadjusted
mean change
score PIV-
Baseline (SD)

Unadjusted
mean change
score PIV-
Baseline (SD)

CIAT Plus versus usual care

M-MAT versus usual care

M-MAT versus CIAT Plus

Adjusted mean
difference
(95% CI)
P value

Adjusted
mean
difference
(95% CI)

Adjusted
mean
difference
(95% CI)

0.96 (4.81)

1.04 (5.17)

2.06 (6.56)

−1.05 (−2.88 to
0.78)

−1.06 (−2.89
to 0.78)

P value

P value

Primary outcome
Aphasia severity, WAB-R
 -AQ

0.36

0.36

−0.004 (−1.77
to 1.76)

1.00

Key secondary outcomes at post-intervention
Aphasia severity, WAB-R-AQ by severity stratum
 Mild

0.51 (4.56)

1.43 (3.57)

1.11 (5.25)

+

+

0.93 (−0.71 to
2.56)

0.26

 Moderate

2.35 (5.60)

−1.33 (6.54)

4.74 (9.00)

+

+

−3.71 (−6.36
to 1.06)

0.006*

 Severe

0.40 (3.68)

8.35 (7.05)

NA (n=0)

+

+

7.83 (0.87 to
14.80)

0.03*

Functional communication,
CETI

2.96 (11.85)

4.29 (10.47)

−1.83 (10.15)

4.32 (0.03 to
8.61)

0.048*

4.64 (0.32 to
8.95)

0.032*

0.31 (−3.81 to
4.44)

0.98

Multimodal communication, −0.30 (4.62)
Scenario Test

1.83 (5.78)

1.20 (4.39)

−1.57 (−3.29 to
0.15)

0.08

0.31 (−1.40 to
2.02)

0.90

1.88 (0.195 to 0.0245*
3.57)

Overall quality of life,
SAQOL-39g: Mean Score

0.06 (0.35)

0.17 (0.38)

−.02 (0.37)

0.09 (−0.03 to
0.21)

0.17

0.20 (0.08 to
0.31)

0.0004*

0.10 (−0.01 to
0.22)

0.085

Communication-r elated
quality of life, SAQOL-39g:
Communication Scale

0.15 (0.64)

0.41 (0.49)

−.03 (0.57)

0.20 (0.01 to
0.39)

0.039*

0.43 (0.24 to
0.62)

<0.0001*

0.24 (0.05 to
0.42)

0.008*

COMPARE naming battery:
80 treated items

15.61 (11.38)

11.30 (10.95)

3.90 (7.73)

10.73 (7.83 to <0.0001*
13.63)

7.49 (4.58 to
10.41)

<0.0001*

−3.24 (−6.05
to 0.43)

0.019*

COMPARE naming battery:
100 untreated items

4.09 (9.86)

2.32 (8.95)

0.51 (10.09)

3.64 (0.79 to
6.50)

0.0081*

1.71 (−1.16 to
4.58)

0.3402

−1.93 (−4.71
to 0.84)

0.2281

2.0 (5.02)

3.07 (6.58)

−2.39 (−4.24
to 0.53)

0.008*

−1.15 (−3.01
to 0.71)

0.32

1.24 (−0.56 to
3.04)

0.24

Key secondary outcomes at 12 week follow-up
Aphasia severity, WAB-R-AQ

0.65 (5.85)

Aphasia severity, WAB-R-AQ by severity stratum
 Mild

0.37 (5.52)

2.38 (3.89)

1.78 (5.84)

+

+

2.03 (0.38 to
3.67)

0.02*

 Moderate

1.40 (7.03)

0.74 (7.56)

6.54 (7.39)

+

+

−0.64 (−3.42
to 2.13)

0.65

2.60 (NA; n=1)

3.00 (3.08)

NA (n=0)

+

+

1.33 (−7.37 to
10.03)

0.76

Functional communication,
CETI

2.64 (15.05)

3.83 (16.58)

0.20 (13.31)

2.14 (−2.31 to
6.59)

0.49

2.68 (−1.77 to
7.13)

0.33

0.54 (−3.73,
4.81)

0.95

Multimodal communication,
Scenario Test

0.57 (6.10)

1.76 (5.90)

1.45 (6.17)

−0.91 (−2.67 to
0.85)

0.45

0.30 (−1.43 to
2.03)

0.91

1.21 (−0.5 to
2.92)

0.22

−0.02 (0.38)

0.08 (0.35)

0.01 (0.36)

−0.03 (−0.15 to
0.10)

0.87

0.07 (−0.05 to
0.19)

0.38

0.09 (−0.25 to
0.211)

0.15

Communication-related
quality of life, SAQOL-39g:
Communication Scale

0.11 (0.60)

0.17 (0.64)

0.11 (0.67)

−0.001 (−0.194
to 0.193)

0.9999

0.036 (−0.157
to 0.229)

0.898

0.037 (−0.151
to 0.225)

0.887

COMPARE naming battery:
80 treated items

9.35 (7.76)

8.61 (8.55)

4.00 (7.80)

4.23 (1.30 to
7.16)

0.002*

4.42 (1.49 to
7.35)

0.001*

0.186 (−2.67 to 0.987
3.04)

COMPARE naming battery:
100 untreated items

3.24 (8.24)

3.46 (9.52)

2.97 (6.76)

0.06 (-2.83 to
2.96)

0.9985

0.26 (-2.64 to
3.16)

0.9753

0.20 9 (2.63 to 0.953
3.02)

 Severe

Overall quality of life,
SAQOL-39g: Mean Score

NB: Bold and *: Statistically significant difference; +These comparisons were not planned for in our statistical analysis plan.23
CETI, Communication Effectiveness Index; CIAT-Plus, Constraint-Induced Aphasia Therapy; COMPARE, Constraint-Induced or Multi-Modality Personalised Aphasia Rehabilitation; M-MAT,
Multimodality Aphasia Therapy; N/A, not available; PIV, Post-intervention; SAQOL-39g, Stroke and Aphasia Quality of Life Scale-39g; WAB-R-AQ, Western Aphasia Battery-Revised Aphasia Quotient.

follow-up, but a global aphasia severity outcome measure was
not used. Similarly, in the Big CACTUS trial7 of computer-based
word retrieval treatment, effects were found on picture naming
but not functional communication, and there was no measure of
change in global aphasia severity.
We demonstrated an unambiguous outcome of significantly
improved word retreival for treated items immediately following
CIAT-Plus and M-MAT compared with UC, with gains exceeding
a previously reported clinically meaningful difference of 10%,7
and maintenance of approximately 50% of the original posttherapy gain at 12 weeks follow-up. The limited generalisation

at the group level to untreated items or to discourse measures
seen here is consistent with the Big CACTUS7 results. There was
a large degree of variability in our discourse measures undermining confidence in their psychometric properties and future
work should explore the stability of these measures and critical
thresholds for meaningful change. Although maintenance of
word retrieval effects were seen at 12 weeks follow-up these were
not seen at the group level for functional communication, multimodal communication or quality of life outcomes. This latter
finding is consistent with the Cochrane Review of SLT5 and a
recent systematic review of maintenance of outcomes following
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employing complex behavioural interventions is lack of participant and therapist blinding. We minimised this risk by using
blinded assessors with checks on potential assessor unblinding
throughout.

SUMMARY

In conclusion, COMPARE is the first multicentre, phase III
RCT in which the effects of two different aphasia treatments,
CIAT-Plus and M-MAT, were compared for people with chronic
aphasia. We found significant improvement in word retrieval,
functional communication, and quality of life immediately
following both treatments and maintenance of word retrieval
effects at follow-up, with a differential benefit of M-MAT for
multimodal communication and communication-related quality
of life and CIAT-Plus for word retrieval. The possible differential
effects by baseline aphasia severity are clinically important for
treatment prescription and require further investigation. Further
research should investigate the impacts of increased dose on
global aphasia severity outcomes and maintenance of effects, and
further refine treatment prescription algorithms.

Figure 3 Comparative mean outcomes measures at baseline, post-
intervention and follow-up. CIAT, Constraint-Induced Aphasia Therapy-
Plus; CETI, Communication Effectiveness Index; COMPARE, Constraint-
Induced or Multi-Modality Personalised Aphasia Rehabilitation; M-MAT,
Multimodality Aphasia Therapy; SAQOL, Stroke and Aphasia Quality of Life;
WAB-R, Western Aphasia Battery-Revised. Error bars represent standard
deviations.
intensive aphasia interventions,29 which showed on average a
50% loss of gains at follow-up. Such loss highlights the need for
research into the impacts of maintenance doses of intervention
on preserving therapeutic gains after intensive aphasia interventions as well as careful examination of participant factors associated with treatment response and maintenance of response.

Study limitations

One limitation of COMPARE concerns the participant numbers
recruited in each severity strata: although we aimed to recruit
participants evenly across the severity strata, 69% had mild
aphasia while only 3% had severe aphasia. Thus, caution is
required in interpreting the results for the severe stratum. A
further potential limitation common to all rehabilitation trials
Table 3

Adverse events and serious adverse events
CIAT Plus

M-MAT

UC

Adverse events

39

36

34

Deaths

0

0

0

Serious adverse events

18

10

8

Serious adverse events
linked to the trial

0

0

0

Participants with serious
adverse events

15 (21.13%)

7 (9.33%)

9 (12.86%)

 0

24 (33.80%)

29 (38.67%)

25 (35.71%)

 1

13 (18.31%)

6 (8%)

8 (11.43%)

 2

1 (1.41%)

1 (1.33%)

1 (1.43%)

 >2

1 (1.41%)

0 (0%)

0 (0%)

CIAT-Plus, Constraint-Induced Aphasia Therapy Plus; M-MAT, Multimodality Aphasia
Therapy; UC, usual care.
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